title: Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
abstract: Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.
authors.affiliation: Transplant Service, University of California, San Francisco, San Francisco, USA. vincentif@surgery.ucsf.edu
authors.forename: Flavio
authors.initials: F
authors.lastname: Vincenti
authors.forename: Amado
authors.initials: A
authors.lastname: de Andrés
authors.forename: Thomas
authors.initials: T
authors.lastname: Becker
authors.forename: Gabriel
authors.initials: G
authors.lastname: Choukroun
authors.forename: Edward
authors.initials: E
authors.lastname: Cole
authors.forename: José M
authors.initials: JM
authors.lastname: González-Posada
authors.forename: Mysore A
authors.initials: MA
authors.lastname: Kumar
authors.forename: Richard
authors.initials: R
authors.lastname: Moore
authors.forename: Silvio
authors.initials: S
authors.lastname: Nadalin
authors.forename: Björn
authors.initials: B
authors.lastname: Nashan
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Saito
authors.forename: Norio
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001706:Biopsy; D065095:Calcineurin Inhibitors; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000378:metabolism; D053645:Interleukin-2 Receptor alpha Subunit; D016030:Kidney Transplantation / Q000379:methods*; D008954:Models, Biological; D010919:Placebos; D011817:Rabbits; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000961:Antilymphocyte Serum; D065095:Calcineurin Inhibitors; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D010919:Placebos; D015375:Receptors, Interleukin-2